Add Idarucizumab To Your DOAC Reversal Protocol for Dabigatran

Idarucizumab (eye-DAIR-yoo-siz-ooh-mab, Praxbind) will be the first reversal agent for ONE of the direct oral anticoagulants (DOACs).

It's an IV monoclonal antibody fragment that binds to the thrombin inhibitor, dabigatran (Pradaxa), to reverse anticoagulation.

But idarucizumab won't work for factor Xa inhibitors...rivaroxaban (Xarelto), apixaban (Eliquis), or edoxaban (Savaysa)...or other direct thrombin inhibitors like argatroban.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals